Boston-based biopharma company Axial Biotherapeutics has secured $10 million in Series B funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced June 20 and financed by Taiho Ventures.
According to its Crunchbase profile, "Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders."
The three-year-old startup has raised two previous funding rounds, including a $25 million Series B round earlier this year.
The round brings total funding raised by Boston companies in science and engineering over the past month to $82 million, an increase of $14 million from the month before. The local science and engineering industry has produced 89 funding rounds over the past year, raking in a total of $1.6 billion in venture funding.
In other local funding news, security and blockchain company Nebulous (Sia & Obelisk) announced a $3.5 million seed funding round on July 10, led by Bain Capital Ventures.
According to Crunchbase, "Nebulous Labs builds Sia, Obelisk and other critical blockchain infrastructure. Sia is the leading decentralized cloud storage network secured by blockchain technology."
Founded in 2014, the company has raised five previous rounds, including a $1.5 million round in 2018.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
